IDEXX Laboratories is a wide-moat, high-quality franchise with a perfect four-quarter earnings beat record and best-in-class margins, but the stock trades at a forward P/E of 34.5x with only 8% headroom to the analyst consensus target — a thin asymmetry that, combined with a confirmed price downtrend, argues for maintaining rather than adding to exposure.
Thesis pillars
- Wide Moat Best In Class Quality→Stable
- Expensive Valuation Thin Upside↓Deteriorating
- Perfect Four Quarter Beat Streak→Stable
- +1 more pillar — see the Why tab for full reasoning
IDEXX Laboratories, Inc. (IDXX) Stock Analysis
Falling Knife setup · Temporary headwind edge
Healthcare · Diagnostics & Research
Wait for pullback to $491.16. Weak momentum; also below 200-day MA (death cross), recent C-suite change — blocks BUY_NOW at $504.70. Engine's entry $491.16 (1 ATR pullback) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: Ortho-Clinical Diagnostics; Negative momentum.
IDEXX Laboratories develops and sells veterinary diagnostics — point-of-care analyzers, reference laboratory services, and practice management software — along with Water quality and Livestock, Poultry and Dairy products, serving customers in more than 175 countries. Revenue is... Read more
Wait for pullback to $491.16. Weak momentum; also below 200-day MA (death cross), recent C-suite change — blocks BUY_NOW at $504.70. Engine's entry $491.16 (1 ATR pullback) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: Ortho-Clinical Diagnostics; Negative momentum. Chart setup: Death cross, below all MAs, RSI 24, MACD bearish. Wide-moat business. Accumulate on weakness. Score 5.5/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
About IDEXX Laboratories, Inc.
About IDEXX Laboratories, Inc.
IDEXX Laboratories directed $251.2 million into R&D in 2025, representing 5.8% of consolidated revenue — implying roughly $4.3 billion in total revenue — across three reportable segments: Companion Animal Group, Water quality products, and Livestock, Poultry and Dairy. Point-of-care diagnostic instruments include the Catalyst One Chemistry Analyzer, ProCyte One hematology analyzer, SediVue Dx urinalysis analyzer, and the IDEXX inVue Dx Cellular Analyzer, launched in late 2024. Reference laboratory services are provided through approximately 80 laboratories in the U.S., Europe, Canada, Australia, Japan, South Korea, New Zealand, and South Africa.
IDEXX earns recurring revenue from consumables sold to its instrument installed base, per-test charges at reference laboratories, and software subscriptions for practice management systems including ezyVet, Animana, IDEXX Neo, and on-premises Cornerstone. Companion animal diagnostic products are sold directly to veterinarians in the U.S. and, outside the U.S., through direct sales forces and, in certain countries, through distributors. Certain instruments and consumables — including ProCyte Dx analyzers, IDEXX inVue Dx cytology consumables, and SediVue Dx instruments — are supplied by sole or single-source manufacturers. Catalyst chemistry slides are supplied exclusively by Ortho-Clinical Diagnostics under agreements running through December 2044, with IDEXX obligated to purchase all its requirements from Ortho for the current test menu. The company also distributes certain Cryptosporidium and Giardia testing kits manufactured by Thermo Fisher Scientific. R&D spending rose from $219.8 million in 2024 and $191.0 million in 2023, reflecting sustained investment in analyzer and test development.
Show full overview
IDEXX's Catalyst instrument platform depends on Ortho-Clinical Diagnostics as the sole supplier of key chemistry slides under supply agreements through December 2044. While the term is long, the agreements allow for early termination in certain circumstances, and after a notice of non-extension they would continue for twelve years. The 10-K notes that sole-sourced products are often proprietary and cannot be readily replaced, that regulatory approval may be required before alternative suppliers could be qualified, and that any inability to obtain adequate quantities from sole and single-source suppliers could materially affect results and potentially result in the permanent loss of customers.
See also: Healthcare · Diagnostics & Research
From IDEXX Laboratories, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-09-14Recent Developments — IDEXX Laboratories, Inc.
Latest news
- NEWS IDEXX Laboratories Inc (IDXX) Valuation: PE, PB & Fair Value Analysis - TradingKey — TradingKey neutral
- NEWS IDEXX Laboratories Inc (IDXX) Valuation: PE, PB & Fair Value Analysis - tradingkey.com — tradingkey.com neutral
- NEWS IDEXX Laboratories Inc (IDXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey — TradingKey neutral
- NEWS Transamerica Mid Cap Growth's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus — GuruFocus neutral
- NEWS IDEXX Laboratories Shares Surge 7% After Beating Q3 Estimates on Strong Diagnostic Demand - MSN — MSN positive
Generated 2026-09-14T07:32:34Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierOrtho-Clinical Diagnostics10-K Item 1A: 'we currently purchase many products, components, and materials from sole or single sources, such as Ortho'
Material Events(8-K, last 90d)
- 2026-03-26Item 5.02MEDIUMEVP Global Strategy & Commercial Nimrata Hunt, PhD, mutually agreed to cease her role effective April 13, 2026, continuing advisory services until July 13, 2026. Separation includes 104-week salary continuation ($1,230,000) plus target bonus ($984,000). Reason: mutual agreement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $491.16. Weak momentum; also below 200-day MA (death cross), recent C-suite change — blocks BUY_NOW at $504.70. Engine's entry $491.16 (1 ATR pullback) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: Ortho-Clinical Diagnostics; Negative momentum. Chart setup: Death cross, below all MAs, RSI 24, MACD bearish. Wide-moat business. Accumulate on weakness. Target $608.06 (+20.5%), stop $464.08 (−8.8%), A.R:R 3.8:1. Score 5.5/10, moderate confidence.
Take-profit target: $608.06 (+20.5% upside). Target $608.06 (+20.5%), stop $464.08 (−8.8%), A.R:R 3.8:1. Stop-loss: $464.08.
Concentration risk — Supplier: Ortho-Clinical Diagnostics; Negative momentum; Below 200-MA, MA slope -2.8%/30d (confirmed downtrend).
IDEXX Laboratories, Inc. trades at a P/E of 35.5 (forward 30.1). TrendMatrix value score: 4.1/10. Verdict: Buy (Wait for Entry).
22 analysts cover IDXX with a consensus score of 4.0/5. Average price target: $699.
What does IDEXX Laboratories, Inc. do?IDEXX Laboratories develops and sells veterinary diagnostics — point-of-care analyzers, reference laboratory services,...
IDEXX Laboratories develops and sells veterinary diagnostics — point-of-care analyzers, reference laboratory services, and practice management software — along with Water quality and Livestock, Poultry and Dairy products, serving customers in more than 175 countries. Revenue is primarily recurring, from consumables sold to an instrument installed base and per-test reference lab fees. R&D expenses were $251.2 million in 2025, representing 5.8% of consolidated revenue.